Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3330296 | 0.86 | PRKCB (1.00) | PRKCB | |
| SCHEMBL24179737 | 0.80 | PRKCB (0.71) | PRKCB | |
| SCHEMBL14103855 | 0.79 | PRKCB (0.79) | PRKCB | |
| SCHEMBL3327583 | 0.79 | PRKCB (1.00) | PRKCB | |
| SCHEMBL3326031 | 0.78 | PRKCB (0.70) | PRKCB | |
| SCHEMBL3328158 | 0.71 | PRKCB (1.00) | PRKCB | |
| SCHEMBL7013709 | 0.69 | PRKCB (1.00) | PRKCB | |
| SCHEMBL7014212 | 0.69 | PRKCB (1.00) | PRKCB | |
| SCHEMBL29638989 | 0.69 | PRKCB (1.00) | PRKCB | |
| SCHEMBL3331560 | 0.69 | PRKCB (1.00) | PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518060-B2 | Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518060-B2 | Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150099743-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PFIZER INC. | 2015-04-09 | — | — | US | disclosed |
| US-20150099743-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PFIZER INC. | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099743-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PRKCB, PRKCA, PRKCQ | PRKCB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.